Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
OncoAlert and ecancer - ESMO 2021 Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
19 Sep 2021
First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer
Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Hou...
First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer ( Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas )
19 Sep 2021
KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-ne...
Prof Hope Rugo - University of California San Francisco, San Francisco, USA
KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )
19 Sep 2021
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trast...
Prof Nadia Harbeck - University of Munich, Munich, Germany
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC ( Prof Nadia Harbeck - University of Munich, Munich, Germany )
18 Sep 2021
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone recept...
Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )
18 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
18 Sep 2021
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast ca...
Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer ( Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom )
17 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )
17 Sep 2021
OncoAlert and ecancer weekly round up for August 23rd - August 29th, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for August 23rd - August 29th, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
31 Aug 2021
OncoAlert and ecancer weekly round up for August 2 - August 14, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for August 2 - August 14, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
16 Aug 2021
OncoAlert and ecancer weekly round up for July 26 - August 1, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for July 26 - August 1, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
2 Aug 2021
Targeted therapy for breast cancer
Dr Aurelio Castrellon - Memorial Healthcare System, Florida, USA
Targeted therapy for breast cancer ( Dr Aurelio Castrellon - Memorial Healthcare System, Florida, USA )
28 Jul 2021